With great interest we read the article by Malavazos et al 1 discussing the possible pathophysiological role for cardiotrophin-1 (CT-1) in left ventricular growth. CT-1 is a member of the interleukin-6 superfamily, which induces cardiomyocyte growth. CT-1 provides prognostic information in patients with untreated essential hypertension and associates with the magnitude of left ventricular hypertrophy in these patients. 2 In contrast, plasma CT-1 is decreased in hypertensive rats. 3 Recently, Natal et al 4 identified adipose tissue as a source of CT-1. They found an elevated level of CT-1 in adult patients affected by the metabolic syndrome. This observation raised the possibility that CT-1 may play a pathophysiological role in metabolic syndrome, acting as a link between obesity-related complications and cardiovascular diseases. In vitro studies demonstrated that chronic administration of CT-1 to adipocytes resulted in the development of insulin resistance. 5 Overweight and related diseases are dramatically increasing problems in adolescents. Therefore, we investigated CT-1 concentrations in adolescents.
It seems that CT-1 is not the link among fat tissue, insulin resistance, and cardiovascular disorders, because CT-1 does not correlate with HbA1c or adiponectin. However, there seems to be a hereditary disposition.
In contrast to adults, CT-1 is in inverse correlation with systolic blood pressure. In animal models with decreased CT-1 in hypertension, hormonal points of difference are discussed, 3 which may also be the underlying mechanism in adolescents. This needs further investigation to reveal the mechanisms leading to morbidity in early life.
